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Abstract 
Background: Concomitant use of anti‑malarial and antiretroviral drugs is increasingly frequent in malaria and HIV 
endemic regions. The aim of the study was to investigate the pharmacokinetic interaction between the anti‑malarial 
drugs, artesunate‑mefloquine and the antiretroviral drug, lopinavir boosted with ritonavir (LPV/r).
Methods: The study was an open‑label, three‑way, sequential, cross‑over, pharmacokinetic study in healthy Thai 
adults. Subjects received the following treatments: Period 1: standard 3‑day artesunate‑mefloquine combination; 
Period 2 (2 months wash‑out): oral LPV/r 400 mg/100 mg twice a day for 14 days; and, Period 3: artesunate‑meflo‑
quine and LPV/r twice a day for 3 days. Sixteen subjects (eight females) were enrolled and pharmacokinetic param‑
eters were determined by non‑compartmental analysis.
Results: In the presence of LPV/r, artesunate Cmax and systemic exposure were significantly increased by 45–80 %, 
while the metabolic ratio of dihydroartemisinin to artesunate was significantly reduced by 72 %. In addition, meflo‑
quine Cmax and systemic exposure were significantly reduced by 19–37 %. In the presence of artesunate‑mefloquine, 
lopinavir Cmax was significantly reduced by 22 % but without significant change in systemic drug exposure. The 90 % 
CI of the geometric mean ratio (GMR) of AUC0−∞ and Cmax were outside the acceptable bioequivalent range for each 
drug. Drug treatments were generally well tolerated with no serious adverse events. Vertigo, nausea and vomiting 
were the most common adverse events reported.
Conclusion: The reduction in systemic exposure of all investigated drugs raises concerns of an increased risk of treat‑
ment failure rate in co‑infected patients and should be further investigated.
© 2015 Rattanapunya et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria and human immunodeficiency virus (HIV) infec-
tions remain major global health burdens [1]. In 2012, 
there was an estimated 207 million cases of malaria 
worldwide, leading to 627,000 deaths [2]. It was esti-
mated that 35 million people were living with human 
immunodeficiency virus (HIV) in 2014 and despite sig-
nificant improvements in HIV prevention and treat-
ment, there were also 2.1 million new infections and 1.5 
million HIV-related deaths worldwide [3]. Management 
of malaria and HIV co-infection is challenging with pos-
sible adverse pathological, clinical, pharmacological, and 
epidemiological interactions between malaria and HIV 
infections and treatments [4–12]. Artemisinin-based 
combination therapy (ACT) is recommended by the 
World Health Organization (WHO) as first-line treat-
ment for acute, uncomplicated Plasmodium falciparum 
malaria [13]. A 3-day course of artesunate-mefloquine 
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combination therapy is commonly used in Southeast 
Asia to cope with multidrug-resistant P. falciparum [13]. 
Artesunate is responsible for the initial rapid decline in 
parasites, while mefloquine persists in the body much 
longer than artesunate to kill the remaining parasites 
[13]. For HIV therapy, ritonavir-boosted protease inhibi-
tors (PIs) are currently recommended by WHO as part 
of second-line antiretroviral therapy for adults. Globally, 
lopinavir/ritonavir (LPV/r) remains the most commonly 
used PI due to its availability as a fixed-dose combination 
and high genetic barrier to resistance [14].
Artesunate is primarily metabolized via esterase-medi-
ated hydrolysis and cytochrome P450 (CYP) 2A6 enzyme 
to the active metabolite dihydroartemisinin [15]. Dihy-
droartemisinin is subsequently metabolized via uridin-
ediphosphate glucuronosyltransferases (UGTs) 1A8/9 
and 2B7 and excreted in the bile [16]. Biotransformation 
of its combination partner mefloquine and LPV/r is via 
CYP3A4 [17–21]. Ritonavir is a potent inhibitor and/or 
inducer of CYP3A4 and several CYP3A4, CYP2B6 and 
CYP2D6 activities [22–25] and is a substrate for several 
membrane transporter proteins [24, 26]. The potential 
for pharmacokinetic drug interactions between ACT, 
notably artemether-lumefantrine and LPV/r has been 
documented [27]. The aim of the current study was to 
investigate the pharmacokinetic interactions between 




This was an open-label, three-way, sequential, cross-
over, pharmacokinetic study in healthy adult volunteers. 
Inclusion criteria included: (1) males and non-pregnant 
females, (2) aged 15–55 years, (3) body weight 40–65 kg, 
(4) non-smokers and non-alcohol drinkers, and, (5) resi-
dents of Mae Sot district, Tak Province. Exclusion criteria 
were those with: (1) hepatic or renal diseases, (2) history 
of using any drug or herbal medicine within the past 
14  days, except antipyretic or anti-emetic drugs, or, (3) 
history of intolerance to artesunate, mefloquine, lopinavir, 
and ritonavir. Written informed consent for study partici-
pation was obtained from each subject before study. The 
minimum requirement of the sample size for the study 
was 16 subjects based on a = 0.05, target power = 80 % 
(b =  0.02) and CV (coefficient of variation) of clearance 
of artesunate (the most variable drug) = 20 %. Consenting 
adults were screened for eligibility and a physical exami-
nation, electrocardiogram (ECG), and laboratory safety 
tests (haematology, biochemistry, urinalysis, and preg-
nancy status) were performed.
The study protocol was approved by the Institute for 
Development of Human Research Protection (IHRP) at 
the Ministry of Public Health in Thailand. Study proce-
dures were conducted in accordance with the Declara-
tion of Helsinki and national and institutional standards.
Drug administration
Figure 1 summarizes the study design. The pharmacoki-
netic sampling was performed sequentially on three 
occasions. Period 1: starting on Day 1, subjects received 
a 3-day course of oral artesunate-mefloquine (artesu-
nate 200 mg on Days 1, 2, and 3 plus mefloquine 750 and 
500 mg on Days 1 and 2, respectively). Artesunate doses 
were given as four tablets (50  mg artesunate per tablet, 
manufactured by Guilin Pharmaceutical Co. Ltd., China). 
Mefloquine doses were given as three tablets on Day 1 
and two tablets on Day 2 (250 mg mefloquine per tablet, 
manufactured by Atlantic Pharmaceutical Ltd., China). 
There was a 2-months wash-out period between Period 
1 and Period 2. Period 2: subjects received oral doses of 
LPV/r (400/100 mg), twice daily, for 14 days (27 doses). 
There was no washout between Period 2 and Period 3. 
Period 3: subjects received the same 3-day oral artesu-
nate-mefloquine combination as in Period 1 in combina-
tion with LPV/r 400/100 mg, twice a day for 3 days.
All subjects were admitted to Mae Sot General Hospi-
tal for observation during the pharmacokinetic sampling 
period and drug dosage was taken at least 2 h before meal 
with water (standard volume 150  mL). All drug doses 
were administered under supervision of the investiga-
tor team. Only analgesics/antipyretics (paracetamol) and 
anti-emetics (dimenhydrinate) were allowed in cases of 
fever and nausea. Drugs with potential interactions with 
the study drugs, i.e., inhibitors and inducers of CYP3A4 
and CYP2A6 were disallowed during the study period 
[28, 29].
Assessments of safety and tolerability
Safety and tolerability of the drugs were assessed based 
on clinical and laboratory assessments during follow-up 
(42 days after Period 1 and 3, and 14 days after Period 2 
according to NIH/NCI common toxicity criteria (CTC) 
grading system for adverse events [30]. Clinical assess-
ments included physical examination and monitoring of 
vital signs and adverse events. Safety laboratory assess-
ments (haematology, biochemistry and urinalysis) were 
performed during each period. All female subjects had 
a pregnancy test (b-human chorionic gonadotropin test) 
performed during each study period. Any abnormal labo-
ratory result was followed up with repeat checks every 
week until it returned to normal.
Blood sample collection for pharmacokinetic assessment
During Period 1 (3-day artesunate-mefloquine alone) 
and Period 3 (3-day artesunate-mefloquine plus LPV/r), 
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blood samples (3  mL each) for determination of meflo-
quine, artesunate and dihydroartemisinin concentrations 
were drawn at pre-dose (before the first dose), and at 
one, two, four, six, eight, 12, 24, 25, 30, 36, 48, and 49 h, 
and seven, 14, 21, 28, 35, and 42 days post-dose (after the 
first dose). During Period 2 and Period 3, blood sample 
(3 mL each) for determination of lopinavir and ritonavir 
concentrations were drawn pre-dose (27th dose), and at 
one, two, four, six, eight, and 12  h post-dose. Immedi-
ately after collection, all blood samples were centrifuged 
(1200×g, 10 min) and the plasma samples were stored at 
−80 °C until analysis.
Measurement of drug concentrations
Analysis of plasma artesunate/dihydroartemisinin and 
mefloquine concentrations was performed at the Cen-
tre of Excellence in Pharmacology and Molecular Biol-
ogy of Malaria and Cholangiocarcinoma, Thammasat 
University. Measurement of plasma concentrations of 
artesunate and its active plasma metabolite dihydroar-
temisinin were performed using liquid chromatogra-
phy mass-spectrometry (LC–MS/MS), according to 
the methods of Thuy et  al. and Lindegardh et  al. with 
modifications [31, 32]. An Agilent 1260 LC system (Agi-
lent Technologies, CA, USA) coupled with an API 5000 
triple quadrupole mass spectrometer (Applied Biosys-
tems/MDS SCIEX, Foster City, USA), with a TurboVTM 
ionization source (TIS) interface operated in the positive 
ion mode, was used for the multiple reaction monitoring 
LC–MS/MS analysis. TIS temperature was maintained at 
500  °C and the TIS voltage was set at 5500 V. Nitrogen 
gas was supplied from an AB-3G (Peak Scientific, Inch-
innan, UK). The curtain, nebulizer (GS1) and TIS (GS2) 
gases were set at 25, 45 and 50 psi, respectively. Quan-
tification was performed using selected reaction moni-
toring for the transitions m/z 402  →  267 (artesunate), 
302  →  163 (dihydroartemisinin), and 300  →  209 (the 
internal standard artemisinin). Chromatographic sepa-
ration was performed using an Elipse XDB C18 column 
(5 µm, 4.6 mm × 150 mm; Thermo Fisher Scientific, MA, 
USA) protected with an Eclipse XDB-C8 guard column 
(Thermo Electron Corporation, MA, USA). The gradient 
mobile phase consisted of a mixture of 10  mM ammo-
nium acetate with 0.1  % glacial acetic acid and acetoni-
trile running at a flow rate of 0.7 mL/min. Total run time 
was 12 min. The limit of quantification (LOQ) for artesu-
nate and dihydroartemisinin were 1 and 2 ng/mL, respec-
tively. Recoveries for both compounds were between 
82–92 and 81–98 %, respectively. The intra- and inter-day 
coefficients of variation (% CV) of artesunate vs dihy-
droartemisinin were 0.7–4.7 vs 4.5–7.3  %; and 3.9–18.3 
vs 4.9–23.1 %, respectively.
Measurement of plasma concentrations of meflo-
quine was performed using high performance liquid 
Fig. 1 Schematic diagram depicting the study design for investigation of pharmacokinetic interaction between a 3‑day artesunate‑mefloquine 
(ARS‑MQ) and lopinavir‑boosted with ritonavir (LPV/r) in healthy Thai subjects
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chromatography (HPLC) according to the method of 
Karbwang et  al. [33] with modifications. Chromato-
graphic separation was performed on a Hypersil ODS 
column (5 µm, 4.6 mm × 250 mm; Thermo Fisher Scien-
tific, MA, USA) protected with an Eclipse XDB-C8 guard 
column (Thermo Electron Corporation, MA, USA). The 
mobile phase consisted of a mixture of phosphate buffer 
(adjusted to pH 2.8 with 1 M phosphoric acid), acetoni-
trile and methanol at a ratio of 40:30:30 % (v:v:v), running 
at the flow rate of 1.0 mL/min. The UV detector was set 
at the wavelength of 220 nm. The assay LOQ was 2.5 ng/
mL. Recovery varied between 83 and 94 %. The intra- and 
inter-day CV of mefloquine were 1.2–6.2 and 4.3–14.5 %, 
respectively.
Lopinavir and ritonavir plasma drug concentrations 
were measured using a validated HPLC assay at the 
PHPT Pharmacology Laboratory, Faculty of Associated 
Medical Sciences, Chiang Mai University [34]. The assay 
LOQ for lopinavir and ritonavir were 100 and 50 ng/mL, 
respectively. The recoveries of lopinavir and ritonavir 
were between 96–112 and 90–94  %, respectively. Intra- 
and inter-assay precisions were less than 4 % of the coef-
ficient of variation. This laboratory participates in the 
NIAID Clinical Pharmacology Quality Assurance Pro-
gramme Proficiency Testing [35].
Quality control (QC) samples for all drugs/metabolite 
under investigation were run in duplicate in each ana-
lytical batch at low, medium and high concentrations. 
Criteria for acceptability were four out of six of the QC 
analyses to lie inside 100 ± 15 % of the nominal values.
Pharmacokinetic analysis
Pharmacokinetic parameters were determined using a 
non-compartmental analysis using WinNonLin soft-
ware (version 6.3, Pharsights, Certara, USA). Con-
centrations of drugs lower than the LOQ levels were 
expressed as zero (undetectable). The Cmax (maximum 
concentration); tmax (time of maximum concentration) 
were determined by direct inspection of the plasma 
concentration–time data. AUC (area under the concen-
tration–time curve) from time 0 to 12 (AUC0−12h), 0 to 
24 (AUC0−24h), 0 to 48 (AUC0−48h), 0 to 168 (AUC0−168h) 
h, and total AUC (AUC0−∞) were calculated using the 
trapezoidal rule. The extrapolated AUC from the last 
sampling time to infinity was estimated from Ct/elimi-
nation rate constant (lz). lz was calculated from at least 
five concentration–time points of elimination phase. 
Apparent oral clearance (CL/F) was calculated as dose/
AUC0−∞. Volume of distribution (Vz/F) was calculated 
as CL/F/lz, and the terminal half-life (t1/2z) was calcu-
lated as 0.693/lz. Metabolic ratio (MR) was defined as 
the ratio between AUC0−24h of dihydroartemisinin and 
artesunate. The geometric mean ratio (GMR: the ratio 
of the value of the parameter for the drug when used 
in combination vs the corresponding value for the drug 
used alone) and its 90  % CI were determined for each 
parameter. A clinically significant pharmacokinetic drug 
interaction occurred whenever the 90 % CI for systemic 
exposure ratio fell entirely outside the equivalence 
range of 0.8–1.25 [36].
Statistical analysis
Statistical analysis of the data was performed using 
SPSS version 16.0 (Gorichem, The Netherlands). Phar-
macokinetic parameters are presented as median and 
95  % confidence intervals (95  % CI). Comparison of 
all pharmacokinetic parameters of artesunate, dihy-
droartemisinin, mefloquine, lopinavir, and ritonavir 
obtained during the two Periods (−1 vs −3 and −2 vs 
−3) were performed using Wilcoxon Signed-Rank test. 
Comparison of the frequency of subjects with adverse 
events between the two groups was performed using a 
Chi-square test. Statistical significance level was set at 
a = 0.05 for all tests.
Results
Subject characteristics
Sixteen healthy subjects (eight males and eight females) 
were included in the pharmacokinetic data analysis; one 
female subject withdrew from the study before Period 
2 due to a positive urine pregnancy test. The median 
(95 % CI) of age and body weight in male vs female sub-
jects was 31 (20–40) vs 29 (21–39) years and 60 (56–62) 
vs 49 (46–53) kg, respectively. All were healthy as veri-
fied by results of clinical, ECG and laboratory investiga-
tions (Table 1).
Table 1 Clinical and laboratory data at baseline
Data are presented as median (95 % CI) values from 16 subjects
Median (95 % CI)
White blood cell count (×10−3/µL) 9.65 (7.651–10.5)
RBC blood cell count (×10−6/µL) 4.58 (3.99–5.23)
Hematocrit (%) 41.3 (35.6–45.2)
Hemoglobin (g/dL) 13.9 (11.6–14.9)
Platelet count (×10−3/µL) 2.42 (2.10–2.70)
BUN (mg/dL) 11.5 (8.9–14.4)
Creatinine (mg/dL) 0.90 (0.70–1.00)
AST (U/L) 18 (16–28)
ALT (U/L) 17 (14–21)
Total protein (g/dL) 7.00 (6.90–7.20)
Albumin (g/dL) 4.40 (4.30–4.50)
Triglyceride (mg/dL) 71 (63–119)
Fasted blood sugar (mg/dL) 91 (81–94)
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Pharmacokinetics of artesunate and dihydroartemisinin 
with and without lopinavir/ritonavir
Median (95  % CI) plasma concentration–time pro-
files of artesunate and dihydroartemisinin following 
administration of a 3-day artesunate-mefloquine alone 
(Period 1) and in combination with LPV/r (Period 3) are 
shown in Fig.  2a, b). None had pre-dose level of either 
artesunate or dihydroartemisinin on any occasion. The 
Fig. 2 Median (95 % CI) plasma concentration–time profiles of (a) artesunate and (b) dihydroartemisinin following administrations of a 3‑day 
artesunate‑mefloquine, with or without steady‑state oral doses of LPV/r
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extrapolated AUC of dihydroartemisinin from the last 
blood sampling time to infinity (AUCt−∞) was less than 
5 %. The pharmacokinetic parameters of artesunate and 
dihydroartemisinin are summarized in Table  2. Inter-
individual variation of artesunate and dihydroartemisinin 
plasma concentrations and pharmacokinetic parameters 
(% CV) ranged from 69 to 400 and 64 to 289.6 %, respec-
tively. Dihydroartemisinin plasma concentrations 1  h 
post-dose on Day 3 was significantly lower when artesu-
nate was given with LPV/r [median (95  % CI) 310 vs 
580 ng/mL, p = 0.044]. AUC0−∞, t1/2z, CL/F and Vz/F of 
artesunate could not be determined due to the rapid elim-
ination of artesunate from the systemic circulation. High 
inter-individual variability in AUC0−24h for artesunate 
(54.4 %) and dihydroartemisinin (80.2 %) were observed. 
In the presence of steady-state LPV/r concentrations, 
artesunate AUC0–24h was significantly increased by about 
80  % (p  =  0.034), dihydroartemisinin Cmax, AUC0−24h 
and AUC0−∞ were significantly decreased by about 
46.6, 58.2 and 48.8 %, respectively (p = 0.023, 0.002, and 
0.006, respectively), while t1/2z was significantly increased 
by 148.5 % (p =  0.028). In addition, the metabolic ratio 
(AUC0–24h ratio) of dihydroartemisinin to artesunate was 
significantly reduced by 72.2 % (p = 0.001).
Pharmacokinetics of mefloquine with and 
without lopinavir/ritonavir
Median (95  % CI) plasma concentration–time profiles of 
mefloquine following administration of a 3-day artesunate-
mefloquine alone (Period 1) and in combination with LPV/r 
(Period 3) are shown in Fig. 3a, b, and its pharmacokinetic 
parameters are summarized in Table 3. None had pre-dose 
level of mefloquine on any occasion. The extrapolated AUC 
of mefloquine from the last blood sampling time to infin-
ity (AUCt−∞) was less than 10 %. In the presence of LPV/r, 
mefloquine Cmax, AUC0−48h, AUC0−168h and AUC0−∞ 
were significantly decreased by 19.3, 28.7, 37.1 and 35.2 %, 
respectively (p = 0.039, 0.001, 0.002 and 0.007, respectively), 
while Vz/F and CL/F were significantly increased by 37.9 
and 54.6 %, respectively (p = 0.004 and 0.010, respectively). 
The inter-individual variability of plasma mefloquine con-
centrations ranged from 34.2 to 96.9 %.
Pharmacokinetics of lopinavir/ritonavir with and 
without artesunate‑mefloquine
Median (95  % CI) plasma concentration–time profiles of 
LPV/r following the administration during Period 2 and 3 
are shown in Fig. 4a, b. None had pre-dose level of lopina-
vir or ritonavir on any occasion. Three subjects in Period 
1 and one subject in Period 3 had undetectable plasma 
lopinavir concentrations until 1 h after the first dose. One 
subject during Periods 1 and 3 each had undetectable 
plasma lopinavir concentrations until 1  h after the first 
dose in Periods 1 and 3. The extrapolated AUC of lopinavir 
or ritonavir from the last blood sampling time to infinity 
(AUCt−∞) was less than 5 %. The inter-individual variabil-
ity of plasma lopinavir and ritonavir concentrations ranged 
from 50.6 to 127.6 and 21.3 to 62.9 %, respectively.
The pharmacokinetics of lopinavir and ritonavir alone 
(Period 2) and in combination with artesunate-meflo-
quine (Period 3) are summarized in Table 4. In the pres-
ence of artesunate-mefloquine, the Cmax of lopinavir 
was significantly decreased by 22.1  % (p  =  0.03), while 
CL/F was significantly increased by 75.4  % (p =  0.023). 
The AUC0–12h, AUC0−∞ and Cmax, of ritonavir were sig-
nificantly decreased by 44.6, 56.3 and 54.9  %, respec-
tively (p  =  0.003, 0.010, and 0.004, respectively), while 
CL/F and Vz/F were significantly increased by 129.1 and 
80.4 %, respectively (p = 0.008 and 0.04, respectively).
Pharmacokinetic interaction between a 3‑day 
artesunate‑mefloquine and lopinavir/ritonavir
The 90  % CI of the GMR of Cmax for dihydrar-
temisinin, lopinavir, ritonavir, and mefloquine, 
Table 2 Pharmacokinetic parameters of artesunate and dihydroartemisininalone and in combination with LPV/r (n = 16)
Data are presented as median (95 % CI) or GMR (90 % CI)




Alone With LPV/r GMR (90 % CI) p value Alone With LPV/r GMR (90 % CI) p value
tmax (h) 1.00 (1.00, 1.00) 1.00 (0.57, 1.43) 1.09 (0.91, 1.31) 0.317 2.00 (1.57, 2.43) 2.00 (1.57, 2.43) 0.96 (0.74, 1.23) 0.803
Cmax (ng/mL) 110 (80, 140) 140 (80, 190) 1.59 (1.03, 2.47) 0.056 580 (290, 870) 310 (80, 540) 0.63 (0.38, 1.06) 0.023*
AUC0–24h (ng h/mL) 200 (160, 230) 240 (190, 290) 1.52 (1.09, 2.10) 0.034* 2370 (1450, 3290) 990 (390, 1590) 0.51 (0.31, 0.85) 0.002*
AUC0–∞ (ng h/mL) – – – – 2680 (1270, 4080) 1370 (620, 2120) 0.55 (0.33, 0.90) 0.006*
t1/2z (h) – – – – 4.02 (1.52, 6.51) 9.99 (3.43, 16.55) 1.89 (1.00, 3.58) 0.028*
CL/F (L/h) – – – – – – – 1.00
Vz/F (L/kg) – – – – – – – 1.00
Metabolic ratio 11.78 (7.56, 15.99) 3.27 (1.62, 4.92) 0.23 (0.11, 0.47) 0.001*
Page 7 of 13Rattanapunya et al. Malar J  (2015) 14:400 
AUC0−12h for ritonavir, AUC0−24h for artesunate and 
dihydroartemisinin, AUC0−168h for mefloquine, and 
AUC0−∞ for mefloquine and ritonavir were out-
side the acceptable bioequivalent range of 0.8-1.25 
(Tables 2, 3 and 4).
Safety and tolerability
Drug treatments were generally well tolerated. Only mild to 
moderate (NIH/NCI Grade 1 and 2) severity grade adverse 
events possibly related to the study drug(s) was observed. 
The frequency of adverse events occurred during the three 
Fig. 3 Median (95 % CI) plasma blood concentration–time profiles of mefloquine following administrations of a 3‑day artesunate‑mefloquine dur‑
ing (a) 48 h and (b) 42 days, with or without steady‑state oral doses of LPV/r
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periods were similar. The adverse events during Period 1 
(artesunate-mefloquine combination) included vertigo (11 
cases, 68.75  %), and nausea/vomiting (eight cases, 50  %). 
The adverse events observed during Period 2 (LPV/r) were 
diarrhoea (eight cases, 50 %) and vertigo (one case, 6.25 %). 
The adverse events observed during Period 3 (artesunate-
mefloquine plus LPV/r) were vertigo (eight cases, 50  %), 
nausea/vomiting (two cases, 12.5  %), poor appetite (two 
cases, 12.5 %), and syncope (one case, 6.25 %). A markedly 
high proportion of subjects (11/16) with increased serum 
triglyceride (about 0.5–2.5 times of baseline) was observed 
during Period 2 after 28 doses of LPV/r.
Discussion
The present study is the first reporting the pharmacoki-
netic interactions between the artesunate-mefloquine 
and LPV/r. Marked changes in the pharmacokinetics of 
artesunate, dihydroartemisinin, mefloquine, lopinavir, 
and ritonavir were observed. All dose regimens dur-
ing the three periods were relatively well tolerated with 
no serious adverse events. Vertigo, nausea and vomiting 
were the most common adverse event during artesunate-
mefloquine in this study. The adverse events occurred 
during administration of LPV/r, diarrhoea and vertigo, 
were similar to previous observations [37–42]. Protease 
inhibitors have been commonly associated with the ele-
vation of triglyceride in all age groups of HIV-infected 
patients [43, 44].
The disposition kinetics of artesunate and dihydroar-
temisinin were in general agreement with that observed 
in healthy Thai subjects [45]. Due to rapid clearance of 
artesunate from the systemic circulation, estimation of 
CL/F, Vz/F, and t1/2z were not possible. In addition, esti-
mation of AUC0−∞ of artesunate is not accurate due to 
a large inter-individual variability of artesunate concen-
trations at the last sampling time point. A relative longer 
t1/2z of dihydroartemisinin was noted compared with a 
previous report (4.02 vs 0.74 h) [46]. Multiple factors com-
plicate comparison of artesunate/dihydroarteminin phar-
macokinetic findings across studies, including differences 
in assay sensitivities and blood sampling schedules. Addi-
tionally, the pharmacology of these agents is known to be 
different between patients with acute malaria and healthy 
volunteers. Mefloquine, a fluorinated 4-quinoline metha-
nol compound, is moderately well absorbed orally in this 
split-dose regimen and extensively distributed. Its elimina-
tion was best described by biexponential disposition kinet-
ics. The systemic exposure of mefloquine given as two 
divided doses of 750 and 500 mg 24 h apart appeared to be 
higher, i.e., ~two-fold relative to that observed in the pre-
vious study in healthy Thai subjects following mefloquine 
alone given at 750 and 500 mg 6 h apart [47, 48]. This was 
attributed to a relatively smaller Vz/F (40  %) and lower 
CL/F (33.4  %) in the current study population. Previous 
studies have shown that different mefloquine products are 
not bio-equivalent [49, 50]. Furthermore, mefloquine con-
centrations in plasma and whole blood have been shown 
to be different [51, 52]. Direct comparison of pharmacoki-
netics particularly systemic exposure should therefore be 
made with caution. The pharmacokinetics of lopinavir and 
ritonavir were in agreement with published data in HIV-
negative volunteers [53].
Two studies have reported the pharmacokinetic dug-
drug interactions between artesunate-based combi-
nations with antiretrovirals drug. In the presence of 
steady-state nevirapine-based HIV-antiviral therapy, 
AUC0−∞ of artesunate was increased 1.5-fold, while 
Vz/F and CL/F were decreased [54]. In contrast, steady-
state ritonavir concentrations significantly reduced the 
AUC0−∞ and Cmax of dihydroartemisinin in healthy sub-
jects [55]. It was thought that the influence of mefloquine 
on pharmacokinetics of artesunate/dihydroartemisinin 
Table 3 Pharmacokinetic parameters of mefloquine when administered alone and in combination with LPV/r
Data are presented as median (95 % CI) and GMR (90 % CI)




Alone With LPV/r GMR (90 % CI)
tmax (h) 33.0 (30.4, 35.5) 33.0 (30.4, 35.5) 1.04 (0.94, 1.14) 0.473
Cmax (ng/mL) 2900 (2440, 3350) 2340 (2050, 2630) 0.87 (0.72, 1.06) 0.039*
AUC0–48h (μg h/mL) 952 (711, 1192) 678 (474, 882) 0.72 (0.54, 0.97) 0.001*
AUC0‑168 (μg h/L) 331 (283, 380) 208 (169, 248) 0.70 (0.55, 0.88) 0.002*
AUC0–∞ (μg h/mL) 1160 (924, 1397) 751 (471, 1031) 0.75 (0.54, 1.04) 0.007*
t1/2z (h) 344 (284, 404) 336 (267, 406) 1.14 (0.90, 1.45) 0.408
CL/F (L/h) 1.08 (0.78, 1.37) 1.67 (1.03, 2.30) 1.33 (0.96, 1.84) 0.004*
Vz/F (L/kg) 9.24 (7.67, 10.81) 12.75 (8.15, 17.35) 1.51 (1.10, 2.08) 0.010*
Page 9 of 13Rattanapunya et al. Malar J  (2015) 14:400 
would only be minimal, if any [47]. The apparent decrease 
in systemic exposure of mefloquine in the presence of 
LPV/r could not be explained by the inhibitory effect of 
LPV/r on CYP3A4-mediated mefloquine metabolism 
[56]. Ritonavir was found to minimally affect mefloquine 
pharmacokinetics despite its strong inhibitory activity on 
CYP3A4 following a single 200 mg dose in healthy volun-
teers [56]. On the other hand, ketoconazole, the CYP3A4 
Fig. 4 Median (95 % CI) plasma concentration–time profiles of (a) lopinavir and (b) ritonavir following oral doses of 400 mg lopinavir plus 100 mg 
ritonavir twice a day, with or without a 3‑day artesunate‑mefloquine
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inhibitor was found to increase plasma mefloquine con-
centrations in healthy subjects when co-administered at 
the dose of 400 mg daily for 10 days [57].
Based on available information, mefloquine does not 
interact with many compounds, although in vitro data sug-
gested that it is a substrate and inhibitor of CYP3A4 and 
P-glycoprotein [17, 58, 59] and animal data indicated that 
it reduces bile production in rats [60]. Since both meflo-
quine and LPV/r are substrates of CYP3A4, the decrease 
in systemic exposure together with an increase in total 
oral clearance without a change in t1/2z of mefloquine may 
suggest the possibility of an inducing effect of LPV/r on 
the intestinal P-glycoprotein [61, 62] and/or a decrease in 
intestinal absorption of mefloquine. The increases in CL/F 
and Vz/F of mefloquine are of similar magnitude, whereas 
t1/2z is unchanged. This supports a decrease in mefloquine 
bioavailability due to LPV/r. The significant decrease in 
mefloquine Cmax and the similarity in magnitude of the 
increases in CL/F and Vz/F of mefloquine without change 
in t1/2z may also support this supposition.
The decrease in systemic exposure of both lopinavir and 
ritonavir was also unexpected in the light of report on the 
inhibitory effect of mefloquine on CYP3A4 [17]. Ritonavir 
auto-induction would be expected to be relatively low, but 
a decrease in intestinal absorption as a consequence of 
inhibitory effect of both mefloquine and ritonavir on bile 
production is possible [23, 60, 63]. Furthermore, because 
ritonavir is a substrate of P-glycoprotein [64], induction of 
gut P-glycoprotein by mefloquine and/or carboxymeflo-
quine may contribute to the decreased drug absorption. 
In a previous study [56], ritonavir steady-state AUC was 
significantly decreased by mefloquine without any change 
in t1/2z following multiple dosing.
The systemic exposure of artesunate and dihydroar-
temisinin were changed in opposite direction in the 
presence of LPV/r (increased artesunate and decreased 
dihydroartemisinin exposure), and thus did not support 
the inducing activity of carboxymefloquine on CYP2A6-
mediated artesunate metabolism [15]. The decrease 
in dihydroartemisinin AUC0-24  h when expressed as 
nmol h/mL unit is much greater than (about 180 %) the 
increase in artesunate AUC which stronger support on 
induction of DHA clearance by LOP/r. The contribution 
of mefloquine on disposition of artesunate/dihydroar-
temisinin was unlikely [47]. In addition, it was noted 
however that the term ‘metabolic ratio’ may not be the 
best to describe the rate of disappearance of artesunate 
in plasma as it may be contributed to by transport pro-
teins. It should be pointed out that the observed systemic 
exposure of dihydroartemisinin may reflect both the 
absorption of artesunate, with subsequent conversion to 
dihydroartemisinin through first-pass or systemic metab-
olism, as well as direct absorption of dihydroartemisinin 
following its formation in the gut through acid-depend-
ent chemical hydrolysis [65].
A large reduction in systemic exposure of both the 
anti-malarial artesunate-mefloquine and the antiretro-
viral LPV/r raises concerns regarding the higher risk of 
treatment failure of both malaria and HIV infection when 
artesunate-mefloquine and LPV/r are co-administered. 
The influence of disease factors (both malaria and HIV) 
add more complexity on the interaction [18, 66–68]. 
On the parasitological aspect, in  vitro studies suggest 
that antiretroviral protease inhibitors may also possess 
anti-malarial activity [69–72] and could potentiate the 
efficacy of anti-malarial drugs [73–75]. Combination of 
Table 4 Pharmacokinetic parameters of  ritonavir and  lopinavir when  administered as  LPV/r alone and  in combination 
with artesunate-mefloquine (n = 16)
Data are presented as median (95 % CI) or GMR (90 % CI)








GMR (90 % CI) p value Alone With artesu‑
nate‑meflo‑
quine
GMR (90 % CI) p value
tmax(h) 4.0 (3.1, 4.8) 4.0 (3.1, 4.8) 0.86 (0.63, 1.17) 0.887 4.0 (3.1, 4.8) 4.0 (3.1, 4.8) 1.03 (0.75, 1.43) 0.942
Cmax  
(μg/mL)
12.36 (10.51, 14.21) 9.62 (7.99, 11.24) 0.77 (0.63, 0.92) 0.030* 1.53 (0.97, 2.08) 0.68 (0.49, 0.87) 0.48 (0.34, 0.69) 0.004*
AUC0–12h  
(μg h/mL)
103.32 (82.62, 124.01) 90.51 (74.86, 106.16) 0.78 (0.62, 0.99) 0.088 8.11 (5.71, 10.50) 4.49 (3.47, 5.50) 0.52 (0.37, 0.74) 0.003*
AUC0–∞  
(μg h/mL)
228.98 (131.13, 326.82) 130.19 (22.61, 237.76) 0.62 (0.38, 1.03) 0.099 10.79 (6.17, 15.40) 4.71 (2.27, 7.15) 0.46 (0.29, 0.71) 0.010*
t1/2z (h) 9.8 (5.4, 14.2) 6.6 (1.8, 11.4) 0.71 (0.45, 1.13) 0.071 4.3 (3.5, 5.1) 3.7 (3.1, 4.4) 0.87 (0.68, 1.11) 0.239
CL/F (L/h) 1.75 (1.01, 2.49) 3.07 (1.18, 4.96) 1.61 (0.98, 2.63) 0.023* 9.27 (4.74, 13.80) 21.24 (8.71, 33.77) 2.19 (1.41, 3.40) 0.008*
Vz/F (L/kg) 0.45 (0.36, 0.54) 0.53 (0.41, 0.65) 1.17 (0.99, 1.38) 0.071 0.97 (0.61, 1.32) 1.75 (0.13, 3.37) 1.90 (1.29, 2.81) 0.041*
Page 11 of 13Rattanapunya et al. Malar J  (2015) 14:400 
mefloquine with ritonavir was shown to produce syn-
ergistic anti-malarial activity against D10 and FAC8 P. 
falciparum clones in  vitro [69]. The most concerning 
finding is a 50  % reduction in the AUC of dihydroarte-
misinin and a significant decrease in Day 7 exposure of 
mefloquine. Artesunate and dihydroartemisinin (three- 
to four-fold potency of artesunate) play an important role 
the first phase of malaria therapy by rapidly lowering the 
parasite burden. Therefore, any decrease in dihydroarte-
misinin exposure as a consequence LPV/r co-administra-
tion may increase the risk of delayed parasite clearance, 
particularly given recent evidence of resistance to the 
artemisinins emerging in Southeast Asia [76]. Current 
guidelines from the WHO for treatment of uncompli-
cated malaria emphasize the need for 3 days of adequate 
ACT exposure to ensure elimination of parasites [13, 
77]. Given that HIV/malaria co-infected patients pre-
sent with higher parasite counts [8, 78], any reduction in 
dihydroartemisinin exposure may predispose patients to 
develop severe malaria due to slower parasite clearance. 
On the other hand, the reduction in systemic clearance of 
mefloquine would increase the risk of parasite recrudes-
cence and/or re-infection. The Day 7 whole blood meflo-
quine concentration has proved to be a useful and simple 
surrogate for therapeutic efficacy of mefloquine [79].
Conclusion
Significant changes in the pharmacokinetics of artesu-
nate/dihydroartemisinin, mefloquine and LPV/r were 
observed in the current study. Despite some limitations 
of the studies (small sample size, no measurement of 
carboxymefloquine and free drug concentrations), these 
data do provide valuable insights into the potential phar-
macokinetic interactions when artesunate-mefloquine 
is co-administered with LPV/r in adults. The complex 
interaction unexplained by the metabolic behaviour 
(both parent drugs and metabolites) may suggest the 
involvement of multiple drug metabolizing enzymes and 
drug transporters. Studies in the target population (HIV 
and malaria co-infection) are needed for more conclusive 
clinical relevance and mechanistic explanation. Until this 
information is available, extrapolating these findings to 
the target population should be performed with caution.
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